52 results about "Axonchoides" patented technology

The invention discloses a functional polypeptide for promoting repair of endometrial stem cells to clitoris sensitive nerves and application, and belongs to the technical field of stem cell repair, the functional polypeptide is used for modifying the endometrial stem cells and Schwann cells through the functional polypeptide, and the clitoris sensitive nerves are repaired in a local slow-release gel delivery mode. The functional polypeptide can activate Laminin expression and regulate and control ECM degradation balance, so that collagen deposition in scar tissues is reduced; in addition, the functional polypeptide can effectively inhibit HOXA1 expression, enhance the axon extension capacity and strengthen the axon microtubulin polymerization capacity of the nerve injury part, and the nerve repair efficiency and the function recovery quality are remarkably improved.

The invention discloses a drug-loaded polymer, an STAT3 inhibitor composite nanoparticle, a preparation method of the STAT3 inhibitor composite nanoparticle and application of the STAT3 inhibitor composite nanoparticle in ophthalmic drugs. The STAT3 inhibitor composite nanoparticle comprises the drug-loaded polymer, an STAT3 inhibitor loaded on the drug-loaded polymer and thermosensitive lipidosome. The drug-loaded polymer is astaxanthin macromolecules, and the astaxanthin macromolecules are prepared by the following steps: in an inert atmosphere, performing condensation polymerization on astaxanthin and HPMDA, and then performing end capping reaction by using mPEG-OH. The compound is used for treating retinal neuron progressive death and ophthalmic diseases caused by axon loss of the retinal neuron progressive death, can show good ROS response and consumption performance, inhibits necrotic apoptosis, apoptosis and pyroptosis of cells, relieves cell death performance, and can show good drug slow release performance.

To provide a method of treating an inflammatory neurological disease or condition that can result in destruction or degeneration of axons or myelin.SOLUTION: Provided is a combination comprising a) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof; and b) one or more drugs selected from the group consisting of I) a compound of a particular formula or a pharmaceutically or veterinarily acceptable salt thereof; ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator); and iii) a signal transducer and activator of transcription 3 (STAT3) inhibitor.SELECTED DRAWING: None

A neurite growth stimulant is a small molecule ENPP1 inhibitor. Small molecule ENPP1 inhibitors are capable of treating central nervous system (CNS) injury and promoting axonal regeneration. The ENPP1 inhibitor in the carrier can be administered at damaged nerves and their cell bodies to promote the regeneration of axons.

The present invention provides the use of the small molecule compound 2-D08 in the preparation of a drug for treating or preventing demyelinating diseases. As a small molecule compound, 2-D08 has a small molecular weight and is easily permeable through the blood-brain barrier to exert central pharmacodynamic effects. Moreover, the chemical synthesis method of 2-D08 is also very mature, which is conducive to reducing the preparation cost of drugs for treating demyelinating diseases, thereby alleviating the medical expenses of patients to a certain extent. 2-D08 can promote the regeneration of myelin sheaths of spinal cord axons, significantly improve the motor ability and nerve function recovery of mice, and is expected to become a disease-modifying treatment drug targeting the origin of brain damage in MS patients, with brain permeability and ion channel selectivity, and has very broad application prospects.

The invention relates to application of GMFB in preparation of a medicine for treating traumatic optic neuropathy. Research finds that on the third day of a rat ONC model, compared with normal control, GMFB expression is remarkably up-regulated; cholera toxin B subunit (Cholera Toxin Subunit B, CTB) tracing shows that the axons of a rat ONC model with the GMFB knocked out are remarkably lengthened (compared with those of a wild rat ONC model), and LFB (luxoLuxol Fast Blue) myelination staining shows that remyelination of the denatured axons can be effectively improved, axon regeneration is promoted, and the visual function is improved by knockout of the GMFB.

The invention discloses a macrophage-platelet targeting delivery system carrying genes and mitochondria as well as a preparation method and application of the macrophage-platelet targeting delivery system. The platelet loaded with the PPAR gamma gene nano-composite is covalently linked to the surface of macrophage through a click chemical reaction, and a novel cell composite carrier is constructed. According to the system, the natural chemotaxis of macrophages to an injured part is fully utilized to realize precise targeting, and PPAR gamma genes and functional mitochondria are synchronously released through platelet activation in an injured microenvironment, so that the energy metabolism and lipid homeostasis of the macrophages are cooperatively regulated and controlled, the cellular burial function of the macrophages is effectively recovered, and tissue repair and regeneration are promoted. Experimental results show that the delivery system is reliable in preparation method and high in targeting efficiency, axon regeneration, myelin sheath repair and motor function recovery can be remarkably promoted in a spinal cord injury model, and a brand-new synergistic treatment strategy is provided for tissue injury repair.

The present invention relates to novel substituted 1H-pyrazol-4-carboxamide compounds as SARM1 inhibitors, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat and prevent pathological conditions involving axial degeneration.

A method of interrupting sympathetic stimulation to the cardiovascular system of a patient in need thereof includes navigating a probe of a hand-held cryogenic therapy apparatus to a stellate ganglion or an autonomic tissue area peripheral to the stellate ganglion of the patient, the probe including a needle configured to produce a cooling zone for focused cryogenic therapy, aligning the needle with one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion, and producing the cooling zone to provide cryogenic therapy to the desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion at a temperature sufficient to cause axonotmesis of the nerves.

The invention discloses a brush motor axon clearance testing device and detection and assembly equipment, the brush motor axon clearance testing device comprises an axon clearance testing mechanism and a jig assembly for a brush motor, the jig assembly is arranged below the axon clearance mechanism, and the brush motor axon clearance testing device is characterized in that the axon clearance testing mechanism comprises a testing installation stand column; an axon testing mechanism used for testing the axon position of the brush motor and a vacant position testing mechanism used for testing the vacant position of the brush motor are vertically arranged on the testing installation stand column in a sliding mode, the axon testing mechanism is vertically arranged on the stand column in a sliding mode, and the vacant position testing mechanism is fixedly installed on one side of the axon testing mechanism; the clearance testing mechanism comprises a clamping jaw assembly used for clamping the outer ring of the head of the magnetic ring of the brush motor and a flexible reset assembly which is connected with the clamping jaw assembly and is axially arranged.

The present invention relates to a nerve conduit including a hollow support including a spring-shaped engraved pattern formed on an inner wall and a biocompatible polymer fiber with a fiber direction aligned parallel to an axonal direction; and an electrically conductive hydrogel applied on the inside or outside of the hollow support, and a method of manufacturing the same.

The present invention relates to a novel injectable protein delivery system and a method for delivering one or more therapeutic agents to the central nervous system (CNS) to promote axonal regeneration. The system is based on the use of a recombinant spider silk protein, referred to as spiroin-SpyTag, which undergoes a rapid transition from a sol state to a gel state when exposed to ultrasonic treatment and incubated at body temperature. This unique characteristic allows the material to be easily injected into a specific target tissue. The methods disclosed herein can deliver a protein therapeutic agent covalently conjugated to spiroin-SpyTag to a subject affected by a CNS disorder or injury. In addition, methods of making such injectable protein delivery systems are fast, convenient, and economical and effective.

The present disclosure provides compounds and methods useful for inhibiting SARM1 and / or treating and / or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).

The present invention provides an NSDP1 micropeptide and its application in repairing demyelinating damage, belonging to the field of biomedicine technology. The NSDP1 polypeptide of the present invention can significantly promote the remyelination of axonal demyelinating damage, providing a new idea and method for repairing nerve demyelinating damage.

The present disclosure relates generally to small molecule inhibitors of axonal degeneration or pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, mixtures of stereoisomers, or prodrugs thereof, methods of making and intermediates thereof, and methods of using the same.

The present disclosure provides compounds and methods useful for inhibiting SARM1 and / or treating and / or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and / or compositions that are useful in medicine, and particularly for treating neurodegeneration (e.g., for reducing axonal degeneration). In some embodiments, the present disclosure provides compounds having a structure as set forth in Formula (I).

Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell populations for improving brain healing after injury. Also provided are methods of improving angiogenesis, axonogenesis, or inducing tissue repair using the disclosed biomaterials. Also provided are methods of making the biomaterials.

The subject invention pertains to a novel injectable protein delivery system and methods for delivering one or more therapeutic agents in the central nervous system (CNS) for promoting axon regeneration. This system is based on the use of a recombinant spider silk protein called spidroin-SpyTag, which undergoes a rapid transition from a sol state to a gel state when exposed to ultrasound treatment and incubated at body temperature. This unique characteristic allows the easy injection of the material into a specific target tissue. The methods herein disclosed allow the delivery of protein therapeutics covalently conjugated to the spidroin-SpyTag to a subject affected by a CNS disorder of injury. Additionally, the method for fabricating this injectable protein delivery system is rapid, convenient, and cost-efficient.

The application discloses a diagnostic marker detection system of a star-shaped glial cell IL-33 knockout EAE model, relates to the technical field of in vitro diagnosis, and comprises the following steps: constructing direction consistency constraint, four-domain prior weight and anchor point consistency scoring; selecting a minimum panel in four domains of inflammation chemotaxis, T cell subgroups, myelin axons and blood brain barrier, and generating Th17 / Th1 and MMP9 / closure protein ratio and chemotaxis combination; implementing standardized collection, platform alignment and bridge calibration, establishing intra-batch / between-batch quality control and time window limitation; performing learning with monotone constraint and two-stage calibration, and reserving animal-to-human population domain adaptation; and outputting star source index, double-threshold value stratification, longitudinal monitoring and interpretable report, so that cross-platform and cross-batch comparability, direction order preservation, traceability and clinical bridgeability are realized, and robust discrimination and reproducibility are improved.

This invention discloses an anisotropic piezoelectric film for nerve repair and its preparation method, belonging to the field of biomedical materials technology. The anisotropic piezoelectric film for nerve repair provided by this invention has a surface with parallel, periodically repeating wavy folds; the wavelength of the wavy folds is 30-50 μm, and the height difference between the peaks and troughs is 10-30 μm; the anisotropic piezoelectric film is an organic piezoelectric polymer film with a thickness of 5-100 μm. The anisotropic piezoelectric film for nerve repair provided by this invention has a regular structure and high orderliness and anisotropy, which can accurately simulate the parallel arrangement of nerve fiber bundles in vivo, exhibiting excellent biomimetic effects. This facilitates the bridging growth of new axons along the injured vertebral segment, avoiding disordered axonal growth.

The present application belongs to the technical field of biological materials, and particularly relates to a microemulsion hydrogel as well as a preparation method and application thereof. The microemulsion hydrogel has a network structure hydrogel, and the network structure hydrogel can improve the solubility of hydrophobic drugs, thereby improving the drug loading capacity of the hydrogel. The drug-loaded hydrogel can slowly and continuously release the drugs at the site of spinal cord injury for repair treatment, avoid side effects caused by excessively high local concentration, and help the repair of movement and nerve function at the injury site. The hydrogel itself can provide a structural scaffold for axon and neuron regeneration for tissue regeneration, and further improve the therapeutic effect of the hydrophobic drugs. Moreover, the preparation method of the microemulsion hydrogel is simple, raw materials are cheap and easy to obtain, and the method is suitable for large-scale production.

Provided are gene therapy vectors, such as adeno-associated virus (AAV), designed for treatment of mutations in the Eukaryotic Translation Initiation Factor 2B Subunit Epsilon (EIF2B5) gene. The EIF2B5 gene provides instructions for making one of five subunits of the elF2B protein, specifically the epsilon subunit of this protein. Such mutations are associated with a disease or disorder such as a leukoencephalopathy, a megalencephalic leukoencephalopathy, a leukodystrophy, a stroke, a migraine, epilepsy, multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD), astrogliosis in aging, Huntington's Disease (HD), amyotrophic lateral sclerosis (ALS), Alexander disease, hepatic encephalopathy (HE), AicardinGoutieres syndrome, CLC-2-related disease, oculodentodigital dysplasia, and / or giant axonal neuropathy. Such leukoencephalopathies or leukodystrophies include, but are not limited to, Vanishing White Matter Disease (VWM). The disclosed gene therapy vectors provide a EIF2B5 cDNA to a subject in need which results in expression of a wild type or functional EIF2B5 protein. Also provided is a new promoter, designated gfa1405, which was designed to target astrocytes and neurons. Thus, compositions, nanoparticles, extracellular vesicles, exosomes, or vector comprising the gfa1405 promoter and methods of its use are also provided.